Türkcü, Fatih Mehmet <br/><br/>
Topical and subconjunctival ranibizumab (lucentis) for corneal neovascularization in experimental rat model.  [electronic resource] 

 -  Cutaneous and ocular toxicology  Jun 2014 
 - 138-44 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1556-9535 
<br/><br/><label>Standard No.: </label>10.3109/15569527.2013.813030  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Topical<br/>Angiogenesis Inhibitors--administration & dosage<br/>Animals<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Antigens, CD34--metabolism<br/>Cornea--drug effects<br/>Corneal Neovascularization--drug therapy<br/>Male<br/>Ranibizumab<br/>Rats, Sprague-Dawley<br/>von Willebrand Factor--metabolism